Open AccessLongitudinally monitored immune biomarkers predict the timing of COVID-19 outcomes
Author(s) -
Gorka Lasso,
Saad Khan,
Stephanie Allen,
Margarette C. Mariano,
Catalina Florez,
Erika P. Orner,
Jose A. Quiroz,
Gregory Quevedo,
Aldo Massimi,
Aditi Hegde,
Ariel S. Wirchnianski,
Robert H. Bortz,
Ryan J. Malonis,
G Georgiev,
Karen Tong,
Natalia G. Herrera,
Nicholas C. Morano,
S. Garforth,
Avinash Malaviya,
Ahmed Khokhar,
Ethan Laudermilch,
M. Eugenia Dieterle,
J. Maximilian Fels,
Denise Haslwanter,
Rohit K. Jangra,
Jason Barnhill,
Steven C. Almo,
Kartik Chandran,
Jonathan R. Lai,
Libusha Kelly,
Johanna P. Daily,
Olivia Vergnolle
Publication year - 2022
Publication title -
plos computational biology/plos computational biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.628
H-Index - 182
eISSN - 1553-7358
pISSN - 1553-734X
DOI - 10.1371/journal.pcbi.1009778
Subject(s) - medicine , immune system , case fatality rate , covid-19 , white blood cell , biomarker , disease , immunology , proportional hazards model , intensive care medicine , epidemiology , biology , infectious disease (medical specialty) , biochemistry
The clinical outcome of SARS-CoV-2 infection varies widely between individuals. Machine learning models can support decision making in healthcare by assessing fatality risk in patients that do not yet show severe signs of COVID-19. Most predictive models rely on static demographic features and clinical values obtained upon hospitalization. However, time-dependent biomarkers associated with COVID-19 severity, such as antibody titers, can substantially contribute to the development of more accurate outcome models. Here we show that models trained on immune biomarkers, longitudinally monitored throughout hospitalization, predicted mortality and were more accurate than models based on demographic and clinical data upon hospital admission. Our best-performing predictive models were based on the temporal analysis of anti-SARS-CoV-2 Spike IgG titers, white blood cell (WBC), neutrophil and lymphocyte counts. These biomarkers, together with C-reactive protein and blood urea nitrogen levels, were found to correlate with severity of disease and mortality in a time-dependent manner. Shapley additive explanations of our model revealed the higher predictive value of day post-symptom onset (PSO) as hospitalization progresses and showed how immune biomarkers contribute to predict mortality. In sum, we demonstrate that the kinetics of immune biomarkers can inform clinical models to serve as a powerful monitoring tool for predicting fatality risk in hospitalized COVID-19 patients, underscoring the importance of contextualizing clinical parameters according to their time post-symptom onset.